Overview

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

Status:
Completed
Trial end date:
2016-11-22
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals
Collaborator:
CTI Clinical Trial and Consulting Services
Treatments:
Eculizumab